TL1A increased the differentiation of peripheral Th17 in rheumatoid arthritis

Cytokine

Volumn 69, Issue 1, 2014, Pages 125-130

  Zhou, Min ^a   Liu, Rui ^a   Su, Dinglei ^a   Feng, Xuebing ^a   Li, Xia ^a,b  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Death receptor 3 (DR3); Rheumatoid arthritis; RORc; Th17; TNF like cytokine 1A (TL1A)

Indexed keywords

DEATH RECEPTOR 3; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR LIKE CYTOKINE 1A; UNCLASSIFIED DRUG; ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; IL17A PROTEIN, HUMAN; RORC PROTEIN, HUMAN; TNFRSF25 PROTEIN, HUMAN; TNFSF15 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TH17 CELL; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ANTIBODIES; ANTIGENS, CD28; ANTIGENS, CD3; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; ENZYME ACTIVATION; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; RNA, MESSENGER; TH17 CELLS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904169713     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.04.007     Document Type: Article

References (31)

1. Weyand C.M. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology 2000, 39:13-18.
2. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37.
3. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze-Koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62:2876-2885.
4. Yang L., Anderson D.E., Baecher-Allan C., Hastings W.D., Bettelli E., Oukka M., et al. IL-21 and TGF-β are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
5. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol 2008, 9:641-649.
6. Volpe E., Servant N., Zollinger R., Bogiatzi S.I., Hupe P., Barillot E., et al. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9:650-657.
7. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
8. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generationof pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
9. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16:479-492.
10. Cassatella M.A., Pereira-da-Silva G., Tinazzi I., Facchetti F., Scapini P., Calzetti F., et al. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 2007, 178:7325-7333.
11. Bamias G., Martin C., Marini M., Hoang S., Mishina M., Ross W.G., et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003, 171:4868-4874.
12. +T-cell immunity against Salmonella. Eur J Immunol 2012, 42:580-588.
13. + T-cell immunity. FASEB J 2012, 26:3575-3586.
14. Biener-Ramanujan E., Gonsky R., Ko B., Targan S.R. FEBS Lett. Functional signaling of membrane-bound TL1A induces IFN-gamma expression. FEBS Lett 2010, 584:2376-2380.
15. Pappu B.P., Borodovsky A., Zheng T.S., Yang X., Wu P., Dong X., et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 2008, 205:1049-1062.
16. Kamada N., Hisamatsu T., Honda H., Kobayashi T., Chinen H., Takayama T., et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010, 16:568-575.
17. Takedatsu H., Michelsen K.S., Wei B., Landers C.J., Thomas L.S., Dhall D., et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008, 2:552-567.
18. Sun X., Zhao J., Liu R., Jia R., Sun L., Li X., et al. Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis. Scand J Rheumatol 2013, 42:97-101.
19. Prehn J.L., Mehdizadeh S., Landers C.J., Luo X., Cha S.C., Wei P., et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol 2004, 112:66-77.
20. Meylan F., Davidson T.S., Kahle E., Kinder M., Acharya K., Jankovic D., et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008, 29:79-89.
21. Zhang J., Wang X., Fahmi H., Wojcik S., Fikes J., Yu Y., et al. Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 2009, 183:5350-5357.
22. Bull M.J., Williams A.S., Mecklenburgh Z., Calder C.J., Twohig J.P., Elford C., et al. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 2008, 205:2457-2464.
23. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442.
24. Aaltonen K.J., Virkki L.M., Malmivaara A., Konttinen Y.T., Nordström D.C., Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 2012, 7:479-492.
25. Sfikakis P.P., Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003, 15:380-386.
26. Schulze-Koops H., Kalden J.R. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001, 15:677-691.
27. Liu C., Xia X., Wu W., Wu R., Tang M., Chen T., et al. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease. Clin Exp Immunol 2013, 73:102-111.
28. Maini R.N., Taylor P.C. Anti-cytokine therapy for rheumatoid Arthritis. Annu Rev Med 2000, 51:207-229.
29. Toussirot E., Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007, 8:2089-2107.
30. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003, 3:900-911.
31. Reichwald K., Jørgensen T.Z., Tougaard P., Skov S. TL1A Induces TCR Independent IL-6 and TNF-α Production and Growth of PLZF(+) Leukocytes. PLoS ONE 2014, 9:e85793.